Inactive Instrument

MannKind Corporation Share Price Nasdaq

Equities

US56400P2011

Biotechnology & Medical Research

End-of-day quote Nasdaq
- USD - Intraday chart for MannKind Corporation
Sales 2024 * 260M 20.71B Sales 2025 * 313M 24.92B Capitalization 1.15B 91.89B
Net income 2024 * 38M 3.03B Net income 2025 * 73M 5.82B EV / Sales 2024 * 3.48 x
Net cash position 2024 * 248M 19.79B Net cash position 2025 * 273M 21.72B EV / Sales 2025 * 2.82 x
P/E ratio 2024 *
32.3 x
P/E ratio 2025 *
18.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.47%
More Fundamentals * Assessed data
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment MT
MannKind Gets FDA Clearance for Clofazimine IND Application DJ
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease CI
MannKind CFO Binder to Retire in April, Names New CFO MT
MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024 CI
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps CI
Transcript : MannKind Corporation, Q4 2023 Earnings Call, Feb 27, 2024
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® CI
Transcript : MannKind Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Transcript : MannKind Corporation - Special Call
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday MT
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million MT
More news
Managers TitleAgeSince
Chief Executive Officer 47 13/03/16
Chief Tech/Sci/R&D Officer 57 30/09/22
Chief Tech/Sci/R&D Officer - 30/08/20
Members of the board TitleAgeSince
Director/Board Member 55 26/11/18
Director/Board Member 69 31/12/19
Director/Board Member 80 30/09/03
More insiders
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Related indices
More about the company